Eliminate hepatitis C Appeal
We are closer than ever to developing an urgently needed hepatitis C vaccine. But in order to get there we need your help.
We are closer than ever to developing an urgently needed hepatitis C vaccine. But in order to get there we need your help.
Research and applications across a range of disease areas to improve allocative efficiency (the maximisation of health outcomes using the most cost-effective mix of interventions and implementation methods).
Optima models have been used extensively to address investment choices related to numerous areas including HIV/AIDS, tuberculosis, malaria, viral hepatitis, and nutrition.
Modelling groups affiliated with the Optima Consortium are continuing to extend the Optima approach, by developing new applications to inform investment of publicly-funded benefits packages for entire health systems, and for optimising implementation options across diverse sectors.
World Bank, The Global Fund, The U.S. Centers for Disease Control, NHMRC.
For any general enquiries relating to this project, please contact:
Head of Infectious Disease Modelling
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2019 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.
